
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a biopharmaceutical company specializing in the development of drugs for metabolic and endocrine disorders. The termination of the master license agreement with Ligand Pharmaceuticals may present some short-term challenges, but the company's strong clinical program pipeline and focus on differentiated assets like VK2809 and VK2735 indicate long-term potential. With upcoming milestones including enrollment completion in VANQUISH-2 and Phase 3 initiation and data readouts, Viking is poised for growth and may become a valuable asset for potential partnerships or strategic alternatives.
Bears say
Viking Therapeutics is currently facing multiple risks in the development of their pipeline, including a lack of credit for their VK2809 and VK0214 programs compared to the focus on their VK2735 program and the risk of not replicating weight loss and tolerability in Phase 3 studies. Additionally, there is a commercial risk of not being able to secure manufacturing agreements for VK2735 or the cost of its API being too high. However, the company does have a strong cash runway that will support development and strategic flexibility for their pipeline, potentially mitigating some of these risks.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares